Treating alzheimer's disease and osteoporosis and reducing aging
View Patent ↗Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
1. A method for treating McArdle disease, comprising administering to a subject in need thereof an effective amount of a composition containing:
a first agent that is an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator;
a second agent that possesses anti-inflammatory activity; and
a third agent that possesses or maintains serotonin activity.
2. The method of claim 1 , wherein the AMPK activator is selected from the group consisting of metformin, phenformin, buformin, 5-aminoimidazole -4-carboxamide ribonucleoside, thienopyridones, resveratrol, nootkatone, thiazole, and adiponectin.
3. The method of claim 1 , wherein the first agent is metformin, phenformin, buformin, ephedrine, thyroxine, salicylanilide, or salicylic acid.
4. The method of claim 3 , wherein the first agent is metformin hydrochloride.
5. The method of claim 1 , wherein the second agent is a non-steroidal anti-inflammatory compound.
6. The method of claim 1 , wherein the second agent is aspirin, diclofenac, ibuprofen, indomethacin, acetaminophen, nimesulide, or a COX-2 inhibitor.
7. The method of claim 6 , wherein the second agent is aspirin.
8. The method of claim 1 , wherein the third agent is serotonin or a serotonin re-uptake inhibitor.
9. The method of claim 8 , wherein the third agent is serotonin sulfate, a serotonin creatinine sulfate complex, or serotonin hydrochloride.
10. The method of claim 1 , wherein the composition contains 5-5,000 mg of the first agent, 1-5,000 mg of the second agent, and 0.1-1,000 mg of the third agent.
11. The method of claim 10 , wherein the composition contains 5-1,500 mg of the first agent, 1-1,000 mg of the second agent, and 0.1-100 mg of the third agent.
12. The method of claim 11 , wherein the composition contains 5-1,000 mg of the first agent, 1-500 mg of the second agent, and 0.1-50 mg of the third agent.
13. The method of claim 1 , wherein the composition contains metformin hydrochloride, aspirin, and a serotonin creatinine sulfate complex.
14. The method of claim 13 , wherein the composition contains 5-5,000 mg of metformin hydrochloride, 1-5,000 mg of aspirin, and 0.1-1,000 mg of the serotonin creatinine sulfate complex.
15. The method of claim 14 , wherein the composition contains 5-1,500 mg of metformin hydrochloride, 1-1,000 mg of aspirin, and 0.1-100 mg of the serotonin creatinine sulfate complex.
16. The method of claim 15 , wherein the composition contains 5-1,000 mg of metformin hydrochloride, 1-500 mg of aspirin, and 0.1-50 mg of the serotonin creatinine sulfate complex.
17. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
18. The method of claim 1 , wherein the composition contains the first, second, and third agents as the only active ingredients.